When was Tharimmune founded?

Tharimmune was founded in 2023 and raised its 1st funding round 1 year after it was founded.

Where is Tharimmune located?

Tharimmune is headquartered in Bridgewater, United States.

How many employees does Tharimmune have?

As of Mar 31, 2026, the latest employee count at Tharimmune is 13.

Is Tharimmune a funded company?

Tharimmune is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Jun 18, 2024.

When was the latest funding round of Tharimmune?

Tharimmune's latest funding was a $***** Post IPO round on Nov 04, 2025, with participation from 16 investors.

Where does Tharimmune rank among its competitors?

Tharimmune ranks 10th amongst 104 active competitors, of which 14 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Tharimmune, which secured $545M in Nov, 2025.

Who are the top competitors of Tharimmune?

Tharimmune's top competitors include OnCusp, CancerVax and Linical. Among them, Tharimmune secured the most recent funding round in November, 2025.

Tharimmune - 2026 Company Profile, Team, Funding, Competitors & Financials

Tharimmune is a public company based in Bridgewater (United States), founded in 2023. It operates as a Clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions. Tharimmune has raised an undisclosed amount in funding from investors like Liberty City Ventures, DRW Trading Group and Gravitas Capital. The company has 104 active competitors, including 14 funded and 16 that have exited. Its top competitors include companies like OnCusp, CancerVax and Linical.

Company Details

Tharimmune, Inc. is a clinical-stage biotechnology company focused on developing therapeutic candidates for rare, inflammatory, and oncologic conditions. They are dedicated to improving the lives of patients through their portfolio of innovative treatments.

Website: tharimmune.com
Email ID: *****@tharimmune.com
Phone Number: +1 **********

Key Metrics

Founded Year

2023

Location

Bridgewater, United States

Stage

Public

Latest Funding Round

Post IPO, Nov 04, 2025, $*****

Investors

Liberty City Ventures & 26 more

Ranked

10^th among 104 active competitors

Employee Count

13 as on Mar 31, 2026

Similar Companies

OnCusp & 116 more

Exit Details

Public

View Tharimmune's full profile

Tharimmune is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
HILLSTREAM BIOPHARMA INC. CIN: 1861657 , United States, Active		-	1 (As on Dec 31, 2020)	-

Tharimmune got listed on Jan 12, 2022.

Click here to take a look at Tharimmune's IPO in detail

Tharimmune has raised funding over 4 rounds. Its first funding round was on Jun 18, 2024. Its latest funding round was a Post IPO round on Nov 04, 2025 for $*****. 16 investors participated in its latest round. Tharimmune has 27 institutional investors.

Here is the list of recent funding rounds of Tharimmune:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 04, 2025	1849165	Post IPO	7686392	8779345	5918349	1691460
Jun 13, 2025	4623889	Post IPO	1783861	7685712	1072477	6399711
Dec 06, 2024	2099062	Post IPO	8601490	5283334	SDS Capital Group & 1 more	3822103

Access funding benchmarks and valuations. Sign up today!

View details of Tharimmune's funding rounds and investors

Tharimmune's employee count trend

Tharimmune has 13 employees as of Mar 26. Here is Tharimmune's employee count trend over the years:

Uncover Tharimmune's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Tharimmune include OnCusp, CancerVax and Linical. Here is the list of Top 10 competitors of Tharimmune, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	OnCusp 2021, New York City (United States), Series A	CRO offering clinical development services for oncology drugs	$139M	Orbimed, F-Prime Capital & 8 others	53/100
2nd	CancerVax 1998, Carlsbad (United States), Series B	Limited information available	$58M	Athenian Venture Partners, endpointgroup.com ... & 11 others	50/100
3rd	Linical 2005, Osaka (Japan), Public	Full service CRO with presence in 20+ countries	-	Japan Asia Investment, SBIC West Japan	48/100
4th	Aster Insights 2006, Tampa (United States), Series C	Provider of contract based oncology clinical trial services	$75M	Clayton Dubilier & Rice, Hearst & 6 others	45/100
5th	Oncotherapeutics 1988, West Hollywood (United States), Acquired	CRO focused on community oncology research, improving cancer therapies' clinical utility	$8.3M	Domain Associates, TVM Capital	44/100
6th	Medivir 1998, Sweden, Public	Medivir - Science working wonders	-	-	41/100
7th	Actithera 2021, Cambridge (United States), Series A	Radiopharmaceutical company developing novel radiotherapeutics for the treatment of cancer through its unique medicinal chemistry platform	$80.8M	M Ventures, 4Bio Capital & 7 others	39/100
8th	Vivia Biotech 2007, Tres Cantos (Spain), Series A	Developer of precision medicine test for hematologic cancers	$7.52M	Suanfarma, Clave	39/100
9th	Medelis 2003, Nashville (United States), Acquired	Oncology CRO providing expert clinical trial management for drug development	-	-	39/100
10th	Tharimmune 2023, Bridgewater (United States), Public	Clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions	-	ARK Investment Management, Liberty City Ventures ... & 25 others	47/100